➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: January 17, 2021

DrugPatentWatch Database Preview

Patent: 8,703,956

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,703,956

Title:	Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
Abstract:	The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD.sub.2 at the CRTH2 receptor.
Inventor(s):	Betancourt; Aimesther (Laval, CA), Lemieux; Marc (Laval, CA), Thibert; Roch (Laval, CA)
Assignee:	Atopix Therapeutics Limited (Abingdon, Oxon, GB)
Application Number:	13/414,328
Patent Claims:	see list of patent claims

Details for Patent 8,703,956

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Glaxosmithkline	NUCALA	mepolizumab	INJECTABLE;SUBCUTANEOUS	761122	001	2019-06-06	Start Trial	Atopix Therapeutics Limited (Abingdon, Oxon, GB)	2031-03-07	RX		search
Glaxosmithkline Llc	NUCALA	mepolizumab	INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER	125526	001	2015-11-04	Start Trial	Atopix Therapeutics Limited (Abingdon, Oxon, GB)	2031-03-07	RX	Orphan	search
Genentech	XOLAIR	omalizumab	VIAL	103976	001	2003-06-20	Start Trial	Atopix Therapeutics Limited (Abingdon, Oxon, GB)	2031-03-07	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 8,703,956

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	201306560	Start Trial
World Intellectual Property Organization (WIPO)	2012119841	Start Trial
United States of America	2012282223	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.